Has Kyle Horner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,739 in general payments to Kyle Horner, MD across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kyle Horner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kyle Horner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kyle Horner, MD

Dermatology · Lebanon, ORNPI 1528124195

Payments from drug & device makers

$1,739in general payments, 2019–2025

Across 126 payments — averaging $13.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$762
AbbVie$500
Amgen$167
Lilly USA, LLC$118
Novartis$96
E.r. Squibb & Sons, L.L.C.$37
plus $59 from 2 others

What the payments were for

Food & beverage$1,67496%
Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	69	$762
AbbVie	32	$500
Amgen	8	$167
Lilly USA, LLC	6	$118
Novartis	6	$96
E.r. Squibb & Sons, L.L.C.	2	$37
Regeneron Healthcare Solutions, Inc.	2	$37
Pfizer	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Skyrizi$101

How this compares

$1,739 in reported general payments places this provider in the 50th percentile of 175 dermatology providers in Oregon.

See all dermatology providers in Oregon →

Medicare billing

Part B allowed, 2024

$223,427

Medicare patients

620

Services billed

2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	17	$356,264
Cosentyx Sensoready (2 Pens)Secukinumab	30	$315,354
OtezlaApremilast	21	$108,085
Betamethasone Dipropionate	143	$7,211
Doxycycline Monohydrate	137	$3,513
Clobetasol Propionate	119	$3,402
Tacrolimus	29	$2,246
Doxycycline Hyclate	89	$2,023
Halobetasol Propionate	25	$1,679
Metronidazole	36	$1,533
Triamcinolone Acetonide	52	$1,331
Mometasone Furoate	67	$1,027
Fluorouracil	16	$1,019
Fluconazole	37	$332
Hydrocortisone	50	$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenOtezla	$167	$108,08521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 175 dermatology providers in Oregon.

Other dermatology in Lebanon

Andrew BlauveltPortland$18.8M
Benjamin EhstPortland$8.1M
Phoebe RichPortland$7.4M
Eric SimpsonPortland$4.8M
Jason HawkesPortland$2M
Alex Ortega LoayzaPortland$1.5M
Nisha DesaiPortland$1.3M
Teri GreilingPortland$994K
Tracy FunkPortland$562K
Collin BlattnerThe Dalles$409K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →